{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:16Z","timestamp":1787008516614,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006163","name":"Project management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006163","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Momentum Data"},{"DOI":"10.13039\/100007472","name":"UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitiligo is an autoimmune skin disorder characterized by depigmented patches of skin, which can have significant psychological impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate the lifetime incidence of vitiligo, overall, by ethnicity and across other sociodemographic subgroups, and to investigate the impacts of vitiligo on mental health, work and healthcare utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Incident cases of vitiligo were identified in the Optimum Patient Care Database of primary care records in the UK between 1 January 2004 and 31 December 2020. The lifetime incidence of vitiligo was estimated at age 80\u2005years using modified time-to-event models with age as the timescale, overall and stratified by ethnicity, sex and deprivation. Depression, anxiety, sleep disturbance, healthcare utilization and work-related outcomes were assessed in the 2\u2005years after vitiligo diagnosis and compared with matched controls without vitiligo. The study protocol for this retrospective observational study was registered with ClinicalTrials.gov (NCT06097494).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 9460 adults and children were newly diagnosed with vitiligo during the study period. The overall cumulative lifetime incidence was 0.92% at 80\u2005years of age [95% confidence interval (CI) 0.90\u20130.94]. Cumulative incidence was similar in female (0.94%, 95% CI 0.92\u20130.97) and male patients (0.89%, 95% CI 0.86\u20130.92). There were substantial differences in lifetime incidence across ethnic groups, listed by Office for National Statistics criteria [Asian 3.58% (95% CI 3.38\u20133.78); Black 2.18% (95% CI 1.85\u20132.50); Mixed\/multiple 2.03% (95% CI 1.58\u20132.47); Other 1.05% (95% CI 0.94\u20131.17); and White 0.73% (95% CI 0.71\u20130.76)]. Compared with matched controls, people with vitiligo had an increased risk of depression [adjusted odds ratio (aOR) 1.08, 95% CI 1.01\u20131.15]; anxiety (aOR 1.19, 95% CI 1.09\u20131.30); depression or anxiety (aOR 1.10, 95% CI 1.03\u20131.17); and sleep disturbance [adjusted hazard ratio (aHR) 1.15, 95% CI 1.02\u20131.31]. People with vitiligo also had a greater number of primary care encounters (adjusted incidence rate ratio 1.29, 95% CI 1.26\u20131.32) and a greater risk of time off work (aHR 1.15, 95% CI 1.06\u20131.24). There was little evidence of disparities in vitiligo-related impacts across ethnic subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians should be aware of the markedly increased incidence of vitiligo in people belonging to Asian, Black, Mixed\/multiple and Other groups. The negative impact of vitiligo on mental health, work and healthcare utilization highlights the importance of monitoring people with vitiligo to identify those who need additional support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae282","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T11:34:24Z","timestamp":1721216064000},"page":"63-71","source":"Crossref","is-referenced-by-count":11,"title":["The lifetime risk and impact of vitiligo across sociodemographic groups: a UK population-based cohort study"],"prefix":"10.1093","volume":"192","author":[{"given":"Viktoria","family":"Eleftheriadou","sequence":"first","affiliation":[{"name":"New Cross Hospital , Royal Wolverhampton NHS Trust, Wolverhampton ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Frimley Health NHS Foundation Trust , Frimley ,","place":["UK"]},{"name":"Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nesnas","sequence":"additional","affiliation":[{"name":"Pfizer Ltd , Tadworth ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nagra","sequence":"additional","affiliation":[{"name":"Pfizer Ltd , Tadworth ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"2024122223524093400_ljae282-B1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"2024122223524093400_ljae282-B2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024122223524093400_ljae282-B3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"2024122223524093400_ljae282-B4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kruger","year":"2012","journal-title":"Int J Dermatol"},{"key":"2024122223524093400_ljae282-B5","doi-asserted-by":"crossref","first-page":"e0163806","DOI":"10.1371\/journal.pone.0163806","article-title":"The prevalence of vitiligo: a meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLOS ONE"},{"key":"2024122223524093400_ljae282-B6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2022.11.027","article-title":"Vitiligo in underrepresented communities: an All of Us database analysis","volume":"88","author":"Ahmed","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024122223524093400_ljae282-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024122223524093400_ljae282-B8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16049","article-title":"The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis","volume":"178","author":"Osinubi","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024122223524093400_ljae282-B9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024122223524093400_ljae282-B10","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1192\/bjo.2022.591","article-title":"The mental health associations of vitiligo: UK population-based cohort study","volume":"8","author":"Thompson","year":"2022","journal-title":"BJPsych Open"},{"key":"2024122223524093400_ljae282-B11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/jdv.14739","article-title":"The prevalence and odds of depression in patients with vitiligo: a meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024122223524093400_ljae282-B12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjd.15199","article-title":"Vitiligo and depression: a systematic review and meta-analysis of observational studies","volume":"177","author":"Lai","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024122223524093400_ljae282-B13","doi-asserted-by":"crossref","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and anxiety: a systematic review and meta-analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PLOS ONE"},{"key":"2024122223524093400_ljae282-B14","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/bjd.15933","article-title":"Quality of life in people with vitiligo: a systematic review and meta-analysis","volume":"177","author":"Morrison","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024122223524093400_ljae282-B15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjd.15560","article-title":"Factors affecting quality of life in patients with vitiligo: a nationwide study","volume":"178","author":"Bae","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024122223524093400_ljae282-B16","first-page":"39","article-title":"Data-resource profile: United Kingdom Optimum Patient Care Research Database","volume":"14","author":"Lynam","year":"2023","journal-title":"Pragmat Obs Res"},{"key":"2024122223524093400_ljae282-B17","author":"Office for National Statistics"},{"key":"2024122223524093400_ljae282-B18"},{"key":"2024122223524093400_ljae282-B19","author":"Empirical Transition Matrix"},{"key":"2024122223524093400_ljae282-B20","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"2024122223524093400_ljae282-B21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(11)60990-2","article-title":"Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study","volume":"378","author":"Gershon","year":"2011","journal-title":"Lancet"},{"key":"2024122223524093400_ljae282-B22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/pds.1934","article-title":"Issues in multiple imputation of missing data for large general practice clinical databases","volume":"19","author":"Marston","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024122223524093400_ljae282-B23","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"2024122223524093400_ljae282-B24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamadermatol.2023.2162","article-title":"Incidence and prevalence of diagnosed vitiligo according to race and ethnicity, age, and sex in the US","volume":"159","author":"Mastacouris","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024122223524093400_ljae282-B25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaad.2018.11.047","article-title":"Vitiligo and major depressive disorder: A bidirectional population-based cohort study","volume":"80","author":"Vallerand","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024122223524093400_ljae282-B26","first-page":"6663646","article-title":"Meta-analytic review of high anxiety comorbidity among patients with vitiligo","volume":"2021","author":"Liu","year":"2021","journal-title":"Biomed Res Int"},{"key":"2024122223524093400_ljae282-B27","doi-asserted-by":"crossref","first-page":"adv6485","DOI":"10.2340\/actadv.v103.6485","article-title":"Perceived stigmatization among dermatological outpatients compared with controls: an observational multicentre study in 17 European countries","volume":"103","author":"Van Beugen","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2024122223524093400_ljae282-B28","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1111\/jdv.19447","article-title":"Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort","volume":"37","author":"Ezzedine","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024122223524093400_ljae282-B29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.2010.09828.x","article-title":"Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo","volume":"163","author":"Thompson","year":"2010","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"2024122223524093400_ljae282-B30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/pde.14775","article-title":"Emerging issues in pediatric skin of color, part 1","volume":"38","author":"Mitchell","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"2024122223524093400_ljae282-B31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2021.5596","article-title":"Assessment of changes in \u00addiversity in dermatology clinical trials between 2010\u20132015 and 2015\u20132020: a systematic review","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae282\/60178725\/ljae282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/1\/63\/60178725\/ljae282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/1\/63\/60178725\/ljae282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T18:52:54Z","timestamp":1734893574000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/1\/63\/7715852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae282","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,7,17]]}}}